Is it necessary to correct the intestinal microbiota disorders in chronic pancreatitis?

The frequency of intestinal microbiota disorders in patients with chronic pancreatitis (CP) is extremely high and can reach 97%. The bacterial overgrowth syndrome (SIBO) and the syndrome of increased epithelial permeability (SPEP), developing against the background of excretory insufficiency of the pancreas, affect the severity of the clinical picture of the disease, reduce the effectiveness of enzyme replacement therapy and generally contribute to the further progression of CP.

The article presents a modern view on the mechanisms of the formation of SIBO and SPEP in CP. There is their aggravating effect on the course of the disease and the aggravation of disorders of the digestive and absorption processes that accompany them is shown and analyzed in the article.

For decontamination of conditionally pathogenic and pathogenic flora, increasing the number and metabolic activity of indigenous microflora in patients with CP, the use of a non-absorbable broad-spectrum antibiotic rifaximin is effective. In order to restore the barrier function of the gastrointestinal mucosa, the drug of choice is rebamipid, a universal cytoprotector that affects all three levels of epithelial tissue protection (preepithelial, epithelial and subepithelial).

Conclusion. CP is characterized by the complexity of its etiology and pathogenesis. Bacterial factors, in particular, SIBO and SPEP, play an essential role in the development of inflammatory changes in the pancreas. In the complex therapy of CP, it is advisable to take measures aimed at correcting disorders of the intestinal microbiota.

1. Bykova A.P., Kozlova I. V. Cytokines in large intestine mucosa and intestinal microbiota in patients with chronic pancreatitis. Medical news of North Caucasus. 2017;12(2): 157–160. (in Russian) doi: 10.14300/mnnc.2017.12044

2. Loranskaya I.D., Mulukhova E. V. The state of microbiocenosis of the small intestine with chronic pancreatitis. Eksp Klin Gastroenterol. 2012;(5): 48–52. (in Russian)

3. Minushkin ON. [Pancreatitis (presentations, epidemiology, etiology, classification)]. Eksp Klin Gastroenterol. 2008;(1):4–10. Russian. PMID: 19145848.

4. Minushkin O. Chronic pancreatitis (definition, classification, pathogenesis, diagnosis, treatment). Meditsinskiy sovet = Medical Council. 2014;(7):20–25. (In Russ.) doi: 10.21518/2079–701X-2014–7–20–25.

5. Bordin D.S., Osipenko Y. V., Vinokurova L. V., Dubtsova E. A. The effect of bacterial overgrowth syndrome in the small intestine on the course of chronic pancreatitis. Eksp Klin Gastroenterol. 2012;(7):43–47. (in Russian)

6. Belousova E. A. Bacterial overgrowth syndrome in chronic pancreatitis. Russian Medical Journal. 2009;(5): 317–321. (in Russian)

7. Zhou C.H., Meng Y. T., Xu J. J., et al. Altered diversity and composition of gut microbiota in Chinese patients with chronic pancreatitis. Pancreatology. 2020 Jan;20(1):16–24. doi: 10.1016/j.pan.2019.11.013.

8. Rey F.E., Faith J. J., Bain J., Muehlbauer M. J., Stevens R. D., Newgard C. B., Gordon J. I. Dissecting the in vivo metabolic potential of two human gut acetogens. J Biol Chem. 2010 Jul 16;285(29):22082–90. doi: 10.1074/jbc.M110.117713.

9. Tan C., Ling Z., Huang Y., et al. Dysbiosis of Intestinal Microbiota Associated With Inflammation Involved in the Progression of Acute Pancreatitis. Pancreas. 2015 Aug;44(6):868–75. doi: 10.1097/MPA.0000000000000355.

10. Gerritsen J., Timmerman H. M., Fuentes S., et al. Correlation between protection against sepsis by probiotic therapy and stimulation of a novel bacterial phylotype. Appl Environ Microbiol. 2011 Nov;77(21):7749–56. doi: 10.1128/AEM.05428–11.

11. Jandhyala S.M., Madhulika A., Deepika G., et al. Altered intestinal microbiota in patients with chronic pancreatitis: implications in diabetes and metabolic abnormalities. Sci Rep. 2017 Mar 3;7:43640. doi: 10.1038/srep43640.

12. Newton K., Dixit V. M. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012 Mar 1;4(3): a006049. doi: 10.1101/cshperspect.a006049.

13. Amyot J., Semache M., Ferdaoussi M., Fontés G., Poitout V. Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via Toll-Like Receptor-4 and NF-κB signalling. PLoS One. 2012;7(4): e36200. doi: 10.1371/journal.pone.0036200. Epub 2012 Apr 27.

14. Ze X., Duncan S. H., Louis P., Flint H. J. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J. 2012 Aug;6(8):1535–43. doi: 10.1038/ismej.2012.4.

15. Minishkin O.N., Ardatskaya M. D., Sergeyev A. V., Volkov M. Yu., Sinitsa A. V. Efficiency of use of Bactistatin in patients with chronic pancreatic. Pharmacology: experiment and clinic. 2006;(3):39–43. (in Russian)

16. Mayev I.V., Kucheryavy Yu. A. Diseases of the pancreas. In 2 vol. Moscow. Medicine, Shiko Publ, 2008. 976 p. (in Russian)

17. Frost F., Kacprowski T., Rühlemann M., Bülow R., et al. Impaired Exocrine Pancreatic Function Associates With Changes in Intestinal Microbiota Composition and Diversity. Gastroenterology. 2019 Mar;156(4):1010–1015. doi: 10.1053/j.gastro.2018.10.047.

18. Capurso G., Signoretti M., Archibugi L., Stigliano S., Delle Fave G. Systematic review and meta-analysis: Small intestinal bacterial overgrowth in chronic pancreatitis. United European Gastroenterol J. 2016 Oct;4(5):697–705. doi: 10.1177/2050640616630117.

19. Yevsikov A. E. Diagnosis of external secretory pancreatic insufficiency and its correction. Thesis paper. Moscow 2021. 105 p. (in Russian)

20. Kucheryavy Yu.A., Oganesyan T. S. Bacterial overgrowth syndrome. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2010;(5):63–68. (in Russian)

21. Denisenko T.L., Perfilova K. M., Yefimova E. I. et al. Bacteriological diagnosis of bacterial overgrowth syndrome in chronic pancreatitis. Medical Almanac. 2010;(2): 239–241. (in Russian)

22. Ministry of Health and Social Development of the Russian Federation. Biochemical study of feces for “dysbacteriosis” (express analysis) – based on the determination of short-chain fatty acids in various biochemical substrates by gas-liquid chromatography. Registration certificate No. ФС-2006/030-bу dated 17.03.2006.

23. Ardatskaya M. D. Bacterial overgrowth syndrome and violation of the processes of digestion and absorption. Polyclinic. 2009;(2):38–40. (in Russian)

24. Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis. 2016 Oct;1(3):135–145. doi: 10.1159/000447252.

25. Simanenkov V. I., Maev I. V., Tkacheva O. N., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi: 10.15829/1728–8800–2021–2758

26. Li X.Y., He C., Zhu Y., Lu N. H. Role of gut microbiota on intestinal barrier function in acute pancreatitis. World J Gastroenterol. 2020 May 14;26(18):2187–2193. doi: 10.3748/wjg.v26.i18.2187.

27. Capurso G., Zerboni G., Signoretti M., Valente R., Stigliano S., Piciucchi M., Delle Fave G. Role of the gut barrier in acute pancreatitis. J Clin Gastroenterol. 2012 Oct;46 Suppl: S46–51. doi: 10.1097/MCG.0b013e3182652096.

28. Sonika U., Goswami P., Th akur B., Yadav R., Das P., Ahuja V., Saraya A. Mechanism of Increased Intestinal Permeability in Acute Pancreatitis: Alteration in Tight Junction Proteins. J Clin Gastroenterol. 2017 May/Jun;51(5):461–466. doi: 10.1097/MCG.0000000000000612.

29. Schietroma M., Pessia B., Carlei F., Mariani P., Sista F., Amicucci G. Intestinal permeability and systemic endotoxemia in patients with acute pancreatitis. Ann Ital Chir. 2016;87:138–44. PMID: 27179282.

30. Grimmig T., Moench R., Kreckel J., Haack S., Rueckert F., Rehder R., Tripathi S., Ribas C., Chandraker A., Germer C. T., Gasser M., Waaga-Gasser A. M. Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. Int J Mol Sci. 2016 Dec 8;17(12):2060. doi: 10.3390/ijms17122060.

31. Michaud D.S., Izard J. Microbiota, oral microbiome, and pancreatic cancer. Cancer J. 2014 May-Jun;20(3):203–6. doi: 10.1097/PPO.0000000000000046.

32. Vétizou M., Pitt J. M., Daillère R., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015 Nov 27;350(6264):1079–84. doi: 10.1126/science.aad1329.

33. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):261–70. doi: 10.1586/egh.10.25.

34. Tanigawa T., Watanabe T., Otani K., et al. Rebamipide inhibits indomethacin-induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of α-defensin 5. Eur J Pharmacol. 2013 Mar 15;704(1–3):64–9. doi: 10.1016/j.ejphar.2013.02.010.

35. Kurata S., Nakashima T., Osaki T., et al. Rebamipide protects small intestinal mucosal injuries caused by indomethacin by modulating intestinal microbiota and the gene expression in intestinal mucosa in a rat model. J Clin Biochem Nutr. 2015 Jan;56(1):20–7. doi: 10.3164/jcbn.14–67.

36. Matysiak-Budnik T., Heyman M., Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003 Jul;18 Suppl 1:55–62. doi: 10.1046/j.1365–2036.18.s1.6.x.

37. Lai Y., Zhong W., Yu T., et al. Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β- Catenin. PLoS One. 2015 Jul 2;10(7): e0132031. doi: 10.1371/journal.pone.0132031.